AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8712392 — intervention group
Group type: COMPARATOR
Intervention: Peter Pan story intraoperatively
Number of subjects: 60
Study 8712392 — intervention group
Group type: COMPARATOR
Intervention: Crusoe story
Number of subjects: 60
Study 1650105 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate (LC)
Number of subjects: 88
Study 1650105 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CRB)
Number of subjects: 88
Study 1650105 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate (SV)
Number of subjects: 88
Study 6407378 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 108
Study 6407378 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 108
Study 6407378 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 108
Study 6407378 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline (1982 follow-up)
Number of subjects: 108
Study 6407378 — intervention group
Group type: COMPARATOR
Intervention: All three antibiotics
Number of subjects: 108
Study 30725315 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxoprofen Hydrogel Transdermal Patch (LOX-T)
Number of subjects: 182
Study 30725315 — intervention group
Group type: COMPARATOR
Intervention: Loxoprofen Tablet (LOX-O)
Number of subjects: 182
Study 27837344 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 102
Study 27837344 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRF)
Number of subjects: 102
Study 26152135 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy (MBCT)
Number of subjects: 0
Study 26152135 — intervention group
Group type: COMPARATOR
Intervention: Supportive Therapy (ST)
Number of subjects: 0
Study 24392551 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on social cognitive theory
Number of subjects: 138
Study 24392551 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 138
Study 21914313 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid artificial cardiac pacing
Number of subjects: 197
Study 21914313 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 197
Study 18274830 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D CT assessment of gastric pouch volume
Number of subjects: 3
Study 18274830 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D CT assessment of pouch area
Number of subjects: 3
Study 18274830 — intervention group
Group type: COMPARATOR
Intervention: UGI study assessment of pouch area
Number of subjects: 3
Study 16944966 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine/abacavir
Number of subjects: 2279
Study 16944966 — intervention group
Group type: COMPARATOR
Intervention: lamivudine/zidovudine/efavirenz (control)
Number of subjects: 2279
Study 15318291 — intervention group
Group type: EXPERIMENTAL
Intervention: SMFA-D
Number of subjects: 69
Study 15318291 — intervention group
Group type: COMPARATOR
Intervention: WOMAC and FFbH-OA
Number of subjects: 69
Study 10925450 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV positive tumour
Number of subjects: 21
Study 10925450 — intervention group
Group type: COMPARATOR
Intervention: Normal epithelium controls
Number of subjects: 21
Study 8818846 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg) administered as a single dose 12, 24 or 48 h before tympanostomy tubes insertion in 17 children with secretory otitis media
Number of subjects: 29
Study 8818846 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg on day 1, 5 mg/kg on days 2-5) administered once daily for 5 days in 12 children with acute otitis media
Number of subjects: 29
Study 1735260 — intervention group
Group type: EXPERIMENTAL
Intervention: NPSV with BIPAP device
Number of subjects: 8
Study 1735260 — intervention group
Group type: EXPERIMENTAL
Intervention: NPSV with Bird 6400ST device
Number of subjects: 8
Study 1735260 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 8
Study 6489326 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of ciprofloxacin (250 mg)
Number of subjects: 6
Study 6489326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of ciprofloxacin (100 mg)
Number of subjects: 6
Study 6489326 — intervention group
Group type: COMPARATOR
Intervention: Both oral and intravenous administration of ciprofloxacin
Number of subjects: 6
Study 2868030 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (full beta-receptor blockade)
Number of subjects: 24
Study 2868030 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem, 240 mg/day
Number of subjects: 24
Study 2868030 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of propranolol and diltiazem, 240 mg/day
Number of subjects: 24
Study 2868030 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of propranolol and diltiazem, 360 mg/day
Number of subjects: 24
Study 2868030 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (low dose)
Number of subjects: 24
Study 2868030 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (high dose)
Number of subjects: 24
Study 2868030 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall clinical response
Number of subjects: 24
Study 2868030 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose diltiazem combination
Number of subjects: 24
Study 2868030 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular function (radionuclide ventriculography)
Number of subjects: 24
Study 29852309 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT for SUD and anxiety disorders (CALM ARC)
Number of subjects: 0
Study 29852309 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study 27999367 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR) - 4 hours time in bed (04:00-08:00)
Number of subjects: 66
Study 27999367 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (TSD) - 0 hours time in bed
Number of subjects: 66
Study 27999367 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery after TSD
Number of subjects: 66
Study 27999367 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery after SR
Number of subjects: 66
Study 27999367 — intervention group
Group type: EXPERIMENTAL
Intervention: Men during late-night hours and the day following sleep loss
Number of subjects: 66
Study 24670079 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary inpatient treatment at the Dutch Asthma Center in Davos, Switzerland for six weeks
Number of subjects: 0
Study 24670079 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary treatment at the outpatient clinic of the Wilhelmina Children's Hospital, Utrecht, the Netherlands for six weeks
Number of subjects: 0
Study 22383237 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.1‐mmol/kg)
Number of subjects: 114
Study 20858263 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective percutaneous coronary intervention of the chronic total occlusion within seven days
Number of subjects: 300
Study 20858263 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 300
Study 19071983 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent language during brief motivational interventions
Number of subjects: 54
Study 16026898 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial central venous catheter (CVC) made of polyurethane integrated with silver, platinum and carbon black (Vantex)
Number of subjects: 539
Study 16026898 — intervention group
Group type: COMPARATOR
Intervention: Control catheter
Number of subjects: 539
Study 14514946 — intervention group
Group type: COMPARATOR
Intervention: DQB1*05 allele
Number of subjects: 38
Study 14514946 — intervention group
Group type: COMPARATOR
Intervention: DQB1*02 allele
Number of subjects: 38
Study 14514946 — intervention group
Group type: COMPARATOR
Intervention: DQB1*03,*04,*06 alleles
Number of subjects: 38
Study 10566642 — intervention group
Group type: COMPARATOR
Intervention: 131I alone (28 patients)
Number of subjects: 51
Study 10566642 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I plus pretreatment with methimazole (30 mg/day; 23 patients)
Number of subjects: 51
Study 8923753 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of extra visual‐spatial cues
Number of subjects: 80
Study 8923753 — intervention group
Group type: COMPARATOR
Intervention: Absence of extra visual‐spatial cues
Number of subjects: 80
Study 8923753 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys with extra cues
Number of subjects: 80
Study 8923753 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls with extra cues
Number of subjects: 80
Study 8923753 — intervention group
Group type: COMPARATOR
Intervention: Boys and girls without extra cues
Number of subjects: 80
Study 8923753 — intervention group
Group type: EXPERIMENTAL
Intervention: Block design test
Number of subjects: 80
Study 8923753 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced KAT cues
Number of subjects: 80
Study 1829901 — intervention group
Group type: EXPERIMENTAL
Intervention: Ser‐Tyr28 human ANH infusion at 0.5 pmol/kg/min for 2 hours under low potassium diet (LK)
Number of subjects: 0
Study 1829901 — intervention group
Group type: EXPERIMENTAL
Intervention: Ser‐Tyr28 human ANH infusion at 0.5 pmol/kg/min for 2 hours under low salt diet (LS)
Number of subjects: 0
Study 1829901 — intervention group
Group type: EXPERIMENTAL
Intervention: Ser‐Tyr28 human ANH infusion at 0.5 pmol/kg/min for 2 hours under high potassium diet (HK)
Number of subjects: 0
Study 1829901 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 6347578 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive patient education (group A)
Number of subjects: 77
Study 6347578 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 77
Study 31591119 — intervention group
Group type: COMPARATOR
Intervention: Nafithromycin (100 to 1200 mg) under fasted or fed condition
Number of subjects: 0
Study 31591119 — intervention group
Group type: COMPARATOR
Intervention: Nafithromycin (400 and 800 mg) under fed condition
Number of subjects: 0
Study 31591119 — intervention group
Group type: COMPARATOR
Intervention: Nafithromycin (600, 800, or 1000 mg) once daily for 7 days under fed condition
Number of subjects: 0
Study 31591119 — intervention group
Group type: COMPARATOR
Intervention: Nafithromycin (600 mg and 800 mg)
Number of subjects: 0
Study 31591119 — intervention group
Group type: COMPARATOR
Intervention: Nafithromycin (1000 mg)
Number of subjects: 0
Study 31591119 — intervention group
Group type: COMPARATOR
Intervention: Nafithromycin (single and multiple dosing)
Number of subjects: 0
Study 28605411 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC) cigarettes; specific dosage and duration not mentioned.
Number of subjects: 0
Study 28605411 — intervention group
Group type: COMPARATOR
Intervention: Statistical methods including inverse probability of compliance weighted (IPCW) estimators; specific details not mentioned.
Number of subjects: 0
Study 26178779 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Vital Sign (EVS) questionnaire
Number of subjects: 30
Study 26178779 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanford Brief Activity Survey (SBAS) questionnaire
Number of subjects: 30
Study 24583274 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated intervention (n=48): six individual treatment visits plus eight weeks of nicotine patch therapy integrated with binge drinking intervention
Number of subjects: 95
Study 24583274 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (n=47): six individual treatment visits plus eight weeks of nicotine patch therapy
Number of subjects: 95
Study 21944429 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal competence
Number of subjects: 96
Study 21944429 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive behaviour
Number of subjects: 96
Study 20076935 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy (LA)
Number of subjects: 0
Study 20076935 — intervention group
Group type: COMPARATOR
Intervention: Extended radical lymphadenectomy
Number of subjects: 0
Study 17663100 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Fengchi (GB 20), Quchi (LI 11), Neiguan (PC 6), Zusanli (ST 36), Fenglong (ST 40), Taicehong (LR 3) and oral administration of Captoril
Number of subjects: 60
Study 17663100 — intervention group
Group type: COMPARATOR
Intervention: Captoril
Number of subjects: 60
Study 16102099 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (80 microg kg(‐1))
Number of subjects: 100
Study 16102099 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (160 microg kg(‐1))
Number of subjects: 100
Study 16102099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11816920 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow‐up home visits by a physician (INT1‐HVP)
Number of subjects: 155
Study 11816920 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction by a physiotherapist in their home (INT2‐PI)
Number of subjects: 155
Study 11816920 — intervention group
Group type: COMPARATOR
Intervention: Standard aftercare (control)
Number of subjects: 155
Study 9222075 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin 200 mg in the morning and placebo in the evening (group A)
Number of subjects: 12
Study 9222075 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily (group B)
Number of subjects: 12
Study 7609517 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg once daily
Number of subjects: 80
Study 7609517 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg once daily
Number of subjects: 80
Study 7609517 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 80
Study 7609517 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 80
Study 3539691 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 hours of bed rest
Number of subjects: 40
Study 3539691 — intervention group
Group type: COMPARATOR
Intervention: 24 hours of bed rest
Number of subjects: 40
Study 3539691 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up ultrasound at 7 days
Number of subjects: 40
Study 28793989 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral tube feeding for ≥7 days in addition to standard care (intravenous rehydration and antiemetic treatment)
Number of subjects: 116
Study 28793989 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (intravenous rehydration and antiemetic treatment)
Number of subjects: 116
Study 28793989 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral tube feeding
Number of subjects: 116
Study 28793989 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 116
Study 25520044 — intervention group
Group type: EXPERIMENTAL
Intervention: Valid cue condition (subliminal cue presented at the same side as the target)
Number of subjects: 0
Study 25520044 — intervention group
Group type: COMPARATOR
Intervention: Invalid cue condition (subliminal cue presented on the opposite side of the target)
Number of subjects: 0
Study 25520044 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition (not explicitly defined but mentioned in Experiment 2)
Number of subjects: 0
Study 22850935 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D(3) supplementation (20,000 IU weekly)
Number of subjects: 68
Study 22850935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 20950168 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodyne® treatment
Number of subjects: 25
Study 20950168 — intervention group
Group type: COMPARATOR
Intervention: HealthLight™ treatment
Number of subjects: 25
Study 19432693 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool-temperature dialysate (HD(35), 35 degrees C)
Number of subjects: 10
Study 19432693 — intervention group
Group type: COMPARATOR
Intervention: Standard-temperature dialysate (HD(37), 37 degrees C)
Number of subjects: 10
Study 17088127 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild to moderate asthma
Number of subjects: 1041
Study 17088127 — intervention group
Group type: COMPARATOR
Intervention: Budesonide or nedocromil and placebo
Number of subjects: 1041
Study 15069115 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiology intervention (immediate reading of mammograms)
Number of subjects: 8543
Study 15069115 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (teaching skills to cope with anxiety)
Number of subjects: 8543
Study 15069115 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 8543
Study 15069115 — intervention group
Group type: COMPARATOR
Intervention: Women with normal mammograms
Number of subjects: 8543
Study 15069115 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with false-positive mammograms (3 months after mammogram)
Number of subjects: 8543
Study 11309768 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy with local irradiation
Number of subjects: 1039
Study 11309768 — intervention group
Group type: COMPARATOR
Intervention: Lumpectomy without local irradiation
Number of subjects: 1039
Study 9441287 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 42
Study 9441287 — intervention group
Group type: COMPARATOR
Intervention: Control group (Ch.T. without urine abnormalities)
Number of subjects: 42
Study 7950228 — intervention group
Group type: EXPERIMENTAL
Intervention: Puji ointment (PJO)
Number of subjects: 628
Study 3586248 — intervention group
Group type: EXPERIMENTAL
Intervention: Flight nurse/flight physician team
Number of subjects: 574
Study 3586248 — intervention group
Group type: COMPARATOR
Intervention: Flight nurse/flight paramedic team
Number of subjects: 574
Study 29602557 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy after mild gallstone pancreatitis
Number of subjects: 262
Study 26889617 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabbage Leaf Wraps (CLWs) for 4 weeks (daily for at least 2 hours)
Number of subjects: 81
Study 26889617 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabbage Leaf Wraps (CLWs) for 4 weeks
Number of subjects: 81
Study 26889617 — intervention group
Group type: COMPARATOR
Intervention: Topical Pain Gel (TPG) (10 mg diclofenac/g, at least once daily)
Number of subjects: 81
Study 26889617 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 81
Study 26201153 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-use catheters
Number of subjects: 0
Study 26201153 — intervention group
Group type: COMPARATOR
Intervention: Single-use catheters
Number of subjects: 0
Study 23744798 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (gum, 6 mg)
Number of subjects: 57
Study 23744798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 21294143 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir
Number of subjects: 27
Study 21294143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 19057883 — intervention group
Group type: EXPERIMENTAL
Intervention: DMARD or TNF-alpha-inhibitors
Number of subjects: 192
Study 16371605 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-directed group (n = 25)
Number of subjects: 50
Study 16371605 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 50
Study 15327421 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mmol/L dMg, 1.25 mmol/L dCa (group IV)
Number of subjects: 22
Study 15327421 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mmol/L dMg, 1.25 mmol/L dCa
Number of subjects: 22
Study 15327421 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mmol/L dMg, 1.75 mmol/L dCa (group II)
Number of subjects: 22
Study 15327421 — intervention group
Group type: COMPARATOR
Intervention: 0.75 mmol/L dMg, 1.75 mmol/L dCa (group I)
Number of subjects: 22
Study 15327421 — intervention group
Group type: COMPARATOR
Intervention: 0.75 mmol/L dMg, 1.25 mmol/L dCa (group III)
Number of subjects: 22
Study 11207080 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ionic contrast media (Group I)
Number of subjects: 3990
Study 11207080 — intervention group
Group type: COMPARATOR
Intervention: Ionic Ioxaglate (Group II)
Number of subjects: 3990
Study 7624818 — intervention group
Group type: EXPERIMENTAL
Intervention: Video viewing
Number of subjects: 1653
Study 7624818 — intervention group
Group type: EXPERIMENTAL
Intervention: Video viewing followed by interactive group session
Number of subjects: 1653
Study 7624818 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1653
Study 2754052 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐nl, 5 million units, subcutaneously daily for 2 weeks then twice weekly for 4 weeks
Number of subjects: 17
Study 2754052 — intervention group
Group type: COMPARATOR
Intervention: Isotretinoin, 1 mg/kg by mouth daily for 6 weeks
Number of subjects: 17
Study 2754052 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment: interferon therapy three times weekly in combination with daily isotretinoin for 6 weeks
Number of subjects: 17
Study 2754052 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment: those whose clearing was incomplete with interferon alone were switched to interferon three times weekly for 6 weeks
Number of subjects: 17
Study 792993 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol tablets (4 mg)
Number of subjects: 14
Study 792993 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of salbutamol tablets and aerosols
Number of subjects: 14
Study 792993 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol aerosol (100 mug)
Number of subjects: 14
Study 792993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 792993 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined active treatment
Number of subjects: 14
Study 31412579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition subsidy with specific target of anemia reduction
Number of subjects: 0
Study 31412579 — intervention group
Group type: COMPARATOR
Intervention: Nutrition subsidy with general target of malnutrition reduction
Number of subjects: 0
Study 27452896 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard SGI (12 sessions, twice weekly)
Number of subjects: 44